{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:14Z","timestamp":1761513194351},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,9,29]],"date-time":"2012-09-29T00:00:00Z","timestamp":1348876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s00280-012-1985-9","type":"journal-article","created":{"date-parts":[[2012,9,30]],"date-time":"2012-09-30T12:32:05Z","timestamp":1349008325000},"page":"883-890","source":"Crossref","is-referenced-by-count":16,"title":["Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer"],"prefix":"10.1007","volume":"70","author":[{"given":"M.","family":"Provencio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Camps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"De las Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Massuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Alberola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cardenal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tar\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,29]]},"reference":[{"key":"1985_CR1","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543\u20133551","journal-title":"J Clin Oncol"},{"key":"1985_CR2","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","volume":"21","author":"F Fossella","year":"2003","unstructured":"Fossella F, Pereira JR, Von Pawel J, Pluzanska A, Gorbounova V et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016\u20133024","journal-title":"J Clin Oncol"},{"key":"1985_CR3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2008.01.010","volume":"3","author":"V Gebbia","year":"2008","unstructured":"Gebbia V, Galette D, Caruso M, Verderame F, Pezzella G et al (2008) Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 3:369\u2013377","journal-title":"Lung Cancer"},{"key":"1985_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48\u201358","journal-title":"Nat Rev Cancer"},{"key":"1985_CR5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<160::AID-IJC10>3.0.CO;2-J","volume":"89","author":"PJ Vaart van de","year":"2010","unstructured":"van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D et al (2010) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89:160\u2013166","journal-title":"Int J Cancer"},{"key":"1985_CR6","first-page":"4899","volume":"62","author":"T Furuta","year":"2002","unstructured":"Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH et al (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells (2002). Cancer Res 62:4899\u20134902","journal-title":"Cancer Res"},{"key":"1985_CR7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/annonc\/mdj135","volume":"17","author":"R de las Penas","year":"2006","unstructured":"de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C et al (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17:668\u2013675","journal-title":"Ann Oncol"},{"key":"1985_CR8","first-page":"5457","volume":"62","author":"R Aloyz","year":"2002","unstructured":"Aloyz R, Zy Xu, Bello V, Bergeron J, Han FY et al (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62:5457\u20135462","journal-title":"Cancer Res"},{"key":"1985_CR9","first-page":"1354","volume":"61","author":"MR Spitz","year":"2001","unstructured":"Spitz MR, Wu X, Wang Y, Wang LE, Shete S et al (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354\u20131357","journal-title":"Cancer Res"},{"key":"1985_CR10","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","volume":"22","author":"S Gurubhagavatula","year":"2004","unstructured":"Gurubhagavatula S, Liu G, Park S, Zhou W, Su L et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594\u20132601","journal-title":"J Clin Oncol"},{"key":"1985_CR11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-07-2179","volume":"14","author":"O Gautschi","year":"2008","unstructured":"Gautschi O, Heigway J, Mack P, Purnell PR, Lara PN et al (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639\u20131648","journal-title":"Clin Cancer Res"},{"key":"1985_CR12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547\u2013566","journal-title":"Nat Rev Drug Discov"},{"key":"1985_CR13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ncb1606","volume":"9","author":"F Mora-Bermudez","year":"2007","unstructured":"Mora-Bermudez F, Gerlich D, Ellenberg J (2007) Maximal chromosomes compaction occurs by axial shortening in anaphase and depends on aurora kinase. Nat Cell Biol 9:822\u2013831","journal-title":"Nat Cell Biol"},{"key":"1985_CR14","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1158\/1078-0432.CCR-05-1964","volume":"12","author":"C Soncini","year":"2006","unstructured":"Soncini C, Carpinelli P, Gianelli L, Fancelli D, Vianello P et al (2006) PHA-680632 a novel aurora kinase inhibitor with potent antitumoural activity. Clin Cancer Res 12:4080\u20134089","journal-title":"Clin Cancer Res"},{"key":"1985_CR15","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1158\/1078-0432.CCR-06-2979","volume":"13","author":"RW Wilkinson","year":"2007","unstructured":"Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ et al (2007) AZD 1152, a selective inhibitor of aurora B kinase, inhibits human xenograft growth by inducing apoptosis. Clin Cancer Res 13:3682\u20133688","journal-title":"Clin Cancer Res"},{"issue":"7304","key":"1985_CR16","first-page":"7310","volume":"10","author":"T Tong","year":"2004","unstructured":"Tong T, Zhong Y, Kong J, Dong L, Song Y et al (2004) Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 10(7304):7310 Erratum in: Clin Cancer Res. 2005 Jun 15;11(12):4635","journal-title":"Clin Cancer Res"},{"key":"1985_CR17","first-page":"991","volume":"9","author":"D Li","year":"2003","unstructured":"Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB et al (2003) Overexpression of oncogenic STK15\/BTAK\/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9:991\u2013997","journal-title":"Clin Cancer Res"},{"key":"1985_CR18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1054\/bjoc.2000.1684","volume":"84","author":"C Sakakura","year":"2001","unstructured":"Sakakura C, Hagiwara A, Yasuoka R, Funjita Y, Nakanishi M et al (2001) Tumour amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84:824\u2013831","journal-title":"Br J Cancer"},{"key":"1985_CR19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/94.17.1320","volume":"94","author":"S Sen","year":"2002","unstructured":"Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez G et al (2002) Amplification\/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94:1320\u20131329","journal-title":"J Natl Cancer Inst"},{"key":"1985_CR20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ijc.1200","volume":"92","author":"Y Miyoshi","year":"2001","unstructured":"Miyoshi Y, Iwao K, Egawa C, Noguchi S (2001) Association of centrosomal kinase STK15\/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92:370\u2013373","journal-title":"Int J Cancer"},{"key":"1985_CR21","first-page":"1420","volume":"9","author":"TM Gritsko","year":"2003","unstructured":"Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M et al (2003) Activation and overexpression of centrosome kinase BTAK\/Aurora- A in human ovarian cancer. Clin Cancer Res 9:1420\u20131426","journal-title":"Clin Cancer Res"},{"key":"1985_CR22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/mc.20098","volume":"43","author":"CM Chung","year":"2005","unstructured":"Chung CM, Man C, Jin Y, Guan XY, Wang Q et al (2005) Amplification and overexpression of aurora kinaseA (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog 43:165\u2013174","journal-title":"Mol Carcinog"},{"key":"1985_CR23","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1158\/1078-0432.CCR-04-1627","volume":"11","author":"E Tanaka","year":"2005","unstructured":"Tanaka E, Hashimoto Y, Ito T, Okumura T, Kan T et al (2005) The clinical significance of Aurora-A\/STK15\/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 11:1827\u20131834","journal-title":"Clin Cancer Res"},{"key":"1985_CR24","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1158\/1078-0432.CCR-04-0806","volume":"10","author":"T Tong","year":"2004","unstructured":"Tong T, Zhong Y, Kong J, Dong L, Song Y et al (2004) Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 10:7304\u20137310","journal-title":"Clin Cancer Res"},{"key":"1985_CR25","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1158\/1078-0432.CCR-05-1650","volume":"12","author":"R Reiter","year":"2006","unstructured":"Reiter R, Gais P, J\u00fctting U, Steuer-Vogt MK, Pickhard A et al (2006) Aurora kinase A messenger RNA overexpression is correlated with tumour progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 12:5136\u20135141","journal-title":"Clin Cancer Res"},{"key":"1985_CR26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/path.2902","volume":"225","author":"Y Ruan","year":"2011","unstructured":"Ruan Y, Song AP, Wang H, Xie YT, Han JY et al (2011) Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population. J Pathol 225:535\u2013543","journal-title":"J Pathol"},{"key":"1985_CR27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10549-010-0936-6","volume":"125","author":"H Sun","year":"2011","unstructured":"Sun H, Bai J, Chen F, Jin Y, Yu Y et al (2011) Lack of an association between AURKA T91A polymorphisms and breast cancer: a meta-analysis involving 32,141 subjects. Breast Cancer Res Treat 125:175\u2013179","journal-title":"Breast Cancer Res Treat"},{"key":"1985_CR28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2010.11.004","volume":"73","author":"L Liu","year":"2011","unstructured":"Liu L, Yuan P, Wu C, Zhang X, Wang F et al (2011) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73:110\u2013115","journal-title":"Lung Cancer"},{"key":"1985_CR29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12032-010-9443-1","volume":"28","author":"S-Z Wei","year":"2011","unstructured":"Wei S-Z, Zhan P, Shi M, Qian Q, Yu L, Song Y (2011) Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 28:315\u2013321","journal-title":"Med Oncol"},{"key":"1985_CR30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.lungcan.2010.10.011","volume":"73","author":"M Yin","year":"2011","unstructured":"Yin M, Yan J, Voutsina J, Tibaldi C, Christiani DC et al (2011) No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 73:370\u2013377","journal-title":"Lung Cancer"},{"key":"1985_CR31","first-page":"2902","volume":"125","author":"HB Wei","year":"2012","unstructured":"Wei HB, Hu J, Shang LH, Zhang YY, Lu FF et al (2012) A meta-analytic review of ERCC1\/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer. Chin Med J 125:2902\u20132907","journal-title":"Chin Med J"},{"key":"1985_CR32","doi-asserted-by":"crossref","first-page":"e38150","DOI":"10.1371\/journal.pone.0038150","volume":"7","author":"JY Yin","year":"2012","unstructured":"Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ (2012) Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 7:e38150","journal-title":"PLoS ONE"},{"key":"1985_CR33","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1158\/1078-0432.CCR-06-2543","volume":"13","author":"DF Giachino","year":"2007","unstructured":"Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S et al (2007) Prospective assessment of XPD Lys751Gln and XDCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13:2876\u20132881","journal-title":"Clin Cancer Res"},{"key":"1985_CR34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejca.2004.08.029","volume":"41","author":"A Martoni","year":"2005","unstructured":"Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F et al (2005) Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41:81\u201392","journal-title":"Eur J Cancer"},{"key":"1985_CR35","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1200\/JCO.2005.04.016","volume":"1","author":"V Georgoulias","year":"2005","unstructured":"Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 1:2937\u20132945","journal-title":"J Clin Oncol"},{"key":"1985_CR36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2008.01.010","volume":"61","author":"V Gebbia","year":"2008","unstructured":"Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F et al (2008) Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 61:369\u2013377","journal-title":"Lung Cancer"},{"key":"1985_CR37","unstructured":"Provencio M, Blanco R, Alberola V, Isla D, Massuti B et al. (2007) Cisplatin plus vinorelbine as first-line treatment for patients with advanced non-small cell lung cancer: molecular correlates. In: 14th European cancer conference, ECCO 14, Barcelona, pp 23\u201327. September, 2007"},{"key":"1985_CR38","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/ijc.22154","volume":"119","author":"H Yang","year":"2006","unstructured":"Yang H, He L, Kruk P, Nicosia SV, Cheng JQ (2006) Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119:2304\u20132312","journal-title":"Int J Cancer"},{"key":"1985_CR39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","volume":"3","author":"S Anand","year":"2003","unstructured":"Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:51\u201362","journal-title":"Cancer Cell"},{"key":"1985_CR40","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.26581","volume":"118","author":"JY Pan","year":"2012","unstructured":"Pan JY, Ajani JA, Gu J, Gong Y, Quin A et al (2012) Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 118:4346\u20134353","journal-title":"Cancer"},{"key":"1985_CR41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2010.05.005","volume":"71","author":"N Vi\u00f1olas","year":"2011","unstructured":"Vi\u00f1olas N, Provencio M, Reguart N, Cardenal F, Alberola V et al (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71:191\u2013198","journal-title":"Lung Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1985-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1985-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1985-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T09:05:57Z","timestamp":1562231157000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1985-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,29]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1985"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1985-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,29]]}}}